Agios Pharmaceuticals, Inc.
AGIO
NASDAQ
Healthcare
$37.58
+1.35%gain today
Market position
Market cap rank
#2011
of 2,614
1-day
+1.35%
1-month
+41.76%
6-month
+38.06%
YTD
+38.26%
1-year
+6.31%
5-year
-34.37%
Key figures
Market cap
$2.23B
P/E (live)
—
price ÷ annual EPS
P/E (reported)
-3.8
FY 2025
EPS
-$7.12
FY 2025
Dividend yield
0.00%
FY 2025
Dividend / share
$0.00
Gross margin
78.67%
FY 2025
Operating margin
-873.87%
FY 2025
Net margin
-764.01%
FY 2025
Return on equity
—
FY 2025
Valuation & financial health
Enterprise value
$1.55B
FY 2025
EV / EBITDA
-3.80
FY 2025
EV / Sales
28.71
FY 2025
Price / book
1.32
FY 2025
Price / sales
29.21
FY 2025
Earnings yield
-26.16%
FY 2025
FCF yield
-23.91%
FY 2025
Debt / equity
0.05
FY 2025
Current ratio
11.46
FY 2025
Return on assets
—
FY 2025
Return on invested capital
Financials · FY 2025
Revenue
$54.03M
Gross profit
$42.51M
Operating income
$-472.13M
EBITDA
$-408.62M
Net income
$-412.78M
Diluted EPS
-$7.12
Shares outstanding
57,972,004
Trading
Open
$37.26
Previous close
$37.08
Day range
$36.52 – $37.75
52-week range
$22.24 – $46.00
50-day avg
$29.84
200-day avg
$31.74
Volume
747,036
Avg volume
1,139,937
Beta
0.59
Price history
+6.31% over 1Y
Compare with peers
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Visit websiteCompany info
CEO
Brian Goff
IPO date
Jul 24, 2013
Headquarters
Cambridge, MA, US
Country
Fundamentals are annual. Figures labeled with their fiscal year.
